2 completed, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Radium 223: new trials by email Literature Review of Radium 223 trials Research Report on Radium 223
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Docetaxel, Radium 223 - Metastatic Castrate Resistant Prostate Cancer | Phase 1 | Completed | Tufts Medical Center | 43 | 2018-01-30 | 2025-10-07 |
| A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer Tasquinimod, Radium 223 - Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-03-01 | 2015-11-20 | |
| Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer Radium 223 - Thyroid Cancer | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 13 | 2014-10-01 | 2019-06-11 |
Prostatic Neoplasms (2) · Thyroid Neoplasms (1)
Gustave Roussy, Cancer Campus, Grand Paris (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Tufts Medical Center (1)
United States (2) · France (1)
Mario Eisenberger, MD (1) · Paul Mathew, MD (1)
2014 (1)